← Eichor
Study identifier: NCT07037875 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

Condition: GERD (Gastroesophageal Reflux Disease)  ·  Sponsor: Cinclus Pharma Holding AB

PhasePhase 3
Planned participants500
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate: * Reduces heartburn symptoms more effectively than lansoprazole * Is safe and well tolerated, based on physical exams, blood tests, and vital signs (heart rate, blood pressure, temperature, and breathing rate) * Causes any side effects during treatment * Has different effects depending on how much of the drug is in the blood * Works differently depending on participants' genes Participants must be between 18 to 80 years old and have EE due to GERD confirmed by an endoscopy. Participants cannot join if they have an active Helicobacter pylori (HP) infection or were treated for HP in the past 6 weeks or have taken antibiotics or bismuth-containing drugs in the past 6 weeks. The study is a randomized, double-blind, active comparator-controlled trial lasting up to 4 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups (about 167 people in each group): * Linaprazan glurate 50 mg twice a day * Linaprazan glurate 50 mg once a day * Lansoprazole 30 mg once a day Everyone will take 2 tablets and…

This description comes directly from the study's public registry record.

Talk to the study team

Rikard Reneland, MD, PhD  ·  +46 70 300 40 88  ·  rikard.reneland@cincluspharma.com

Kajsa Larsson, MD, PhD  ·  +46 70 675 01 28  ·  kajsa.larsson@cincluspharma.com

Always discuss trial participation with your own doctor first.

Locations (75)

Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski - 2003" OODDupnitsa, Dupnitsa, BulgariaNot Yet Recruiting
Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOODGorna Oryahovitsa, Gorna Oryahovitsa, BulgariaRecruiting
Diagnosis - Consulting Centre 1Sliven, Sliven, BulgariaNot Yet Recruiting
Medical Center "Orange"Sofia, Sofia City Province, BulgariaNot Yet Recruiting
Multiprofile Hospital for Active Treatment - "Vita"Sofia, Sofia City Province, BulgariaNot Yet Recruiting
Diagnostic and Consulting Center AlexandrovskaSofia, Sofia City Province, BulgariaRecruiting
Diagnostic Consultative Center - Focus-5Sofia, Sofia City Province, BulgariaNot Yet Recruiting
Medical Center HeraSofia, Sofia City Province, BulgariaRecruiting
University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL"Sofia, Sofia City Province, BulgariaNot Yet Recruiting
University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. PirogovSofia, Sofia City Province, BulgariaNot Yet Recruiting
20th Diagnostic Consultancy CenterSofia, Sofia City Province, BulgariaRecruiting
Medical Center HeraKyustendil, BulgariaNot Yet Recruiting

+ 63 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07037875